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Abstract
Chagas disease, caused by Trypanosoma cruzi, is considered an endemic disease that 
affects millions of people causing generating health, economic and social problems. This 
study provides a review on research and development of new therapies for Chagas based 
in natural products of plant origin. We observed that there are more than 400 plant spe-
cies that have been evaluated against different models of Chagas disease, and in some 
cases, there are interesting results. Challenge that hinders research work is the puri-
fication of the active compound and standardization of the chemical profile of whole 
extracts. The principal common factor that delays clinical testing is the lack of investment 
for the development of these products at the clinical phase. In the search of a natural, low 
cost and available drug for Chagas disease, we propose the use of new methodologies to 
overcome the existing challenges. The use of plant metabolomic technique is proposed 
as an option with high potential for the identification of biomarkers that could allow the 
standardization of chemical profiles. Furthermore, we describe the importance of apply-
ing good agricultural and manufacturing practices for reaching a successful development 
of quality phytotherapeutic products.
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1. Introduction
“It does not explode like bombs or sound like shots. As hunger kills silently. As hunger kills 
the quiet, those who live condemned silence and die doomed to oblivion. The tragedy that 
does not ring, sick who do not pay, a disease that does not sell. Chagas disease is not a busi-
ness that appeals to the pharmaceutical industry, nor is it a matter of interest to politicians 
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or journalists. Choose your victims in the pit. He bites them and slowly, little by little, and he 
ends up with them. Their victims have no rights, no money to buy the rights they do not have. 
They do not even have the right to know what they die from.” Informe clínico, by Uruguayan 
writer Eduardo Galeano, in “Chagas, una tragedia silenciosa,” Médicos Sin Fronteras, Editorial 
Losada, 2005.
Chagas disease is caused by Trypanosoma cruzi, transmitted to humans through the bite of 
Triatomine spp. by contaminated defecation rubbed on the mucosa. Transmission can also occur 
by ingestion of contaminated food, through blood transfusion or vertical transmission from 
mother to child [1]. It is worth to highlight that this endemic disease causes health, economic, and 
social problems affecting 6–7 million people in 21 countries from Central and South America. 
Moreover, 25 million people remain under risk of infection, given the high levels of population 
mobility from Latin America to the rest of the world or residence in endemic regions [2, 3].
Trypanosoma cruzi (T. cruzi) presents a quite complex cycle with different forms throughout its 
evolutionary cycle. In the insect vector, different stages can be observed. The spheromastigote, 
characterized as the round form of the organism, is predominantly found in the stomach of 
the organism. The epimastigote stage is found in the gut of the vector, at this stage, the T. cruzi 
is intensively multiplies by binary division. And finally the metacyclic trypomastigote stage, 
which is the infecting form for the vertebrate host [4, 5]. When the insect feeds on human 
blood, it defecates on the host’s skin, releasing into the feces parasites in the metacyclic try-
pomastigote form. Upon entry to the organ, trypanosomes are disseminated via the blood or 
lymphatic, affecting various organs mainly the heart, nervous system, muscle, and digestive 
system. Once the parasites reach the tissues they reproduce, passing through a non- flagellated 
stage, called amastigote, which is able to actively multiply themselves forming pseudocysts, 
where they are to be transformed into trypomastigotes that are later to be released [6]. It 
is estimated that the incubation period of the disease is between 5 and 12 days relative to 
each case, as well as the appearance of symptoms and the intensity of them. Often, cases are 
asymptomatic so timely diagnosis can be very difficult. Undiagnosed individuals may lead 
to conditions like serious cardiac and digestive conditions begin to arise that may lead to 
death [7]. It is possible to observe three well-defined stages of the disease. The initial stage 
is called acute or initial, which lasts approximately 2–4 months after infection. At this stage, 
many people do not have symptoms. Most patients with symptoms suffer from variable fever, 
malaise, irritability, headache, enlargement of the liver, spleen, and lymph nodes. When the 
inoculation is close to the ocular area, the characteristic chagoma is observed as well as a uni-
lateral edema of both eyelids [8]. At this stage, the parasite can be found in the blood. Some 
acute cases can become deadly and many of these turn out to be young children and patients, 
who are immunocompromised (e.g. people infected with HIV), who may develop acute myo-
carditis or meningoencephalitis [9]. Then a second indeterminate or also called latent stage 
in which the infection becomes undetectable and is usually asymptomatic. It usually occurs 
between week 8 and 10 of the acute phase and it can last for months or even years. It is esti-
mated that approximately 30% of individuals who reach this stage develop digestive, cardiac, 
and neurological problems [10]. Finally, the chronic phase which appears in the latter part of 
the infection, it is characterized by cardiac and intestinal problems. Sudden death can occur 
without the individual developing heart problems [11].
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The diagnosis of this disease is relative to infection of the patient. Direct methods (direct 
microscopic observation, xenodiagnosis, PCR, etc.) based on the detection of genetic mate-
rial or parasites or indirect methods (ELISA, IFI, Western blot, etc.) based on the detection of 
specific antibodies against T. cruzi, mainly used in the chronic stage, either symptomatic or 
asymptomatic. These are usually used mainly in the acute phase, in the case of immunosup-
pressed persons or under 6 months of age [12].
Unfortunately, an effective chemotherapy for all the clinical forms of the disease has not 
been reached, although fair enough time has passed by since the discovery of the disease in 
1909 by a Brazilian Doctor, Carlos Ribeiro Justiniano Chagas [2]. This intractable situation is 
the typical case of neglected diseases, where the lack of adequate therapies or effective vac-
cines provoque health crisis [13]. Despite the revealing evidence of the current situation has 
not received sufficient attention from the pharmaceutical industry, mainly due to economic 
considerations. The current pharmacological treatments are based on two nitroheterocycles 
compounds, which were discovered more than 30 years ago: nifurtimox (Nfx, N-(3-methyl-
1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitro-2 Methionine, Lampit®, suspended production, 
and sale by Bayer), and benznidazole (Bnz, N-benzyl-2-(2-nitroimidazol-1-yl) acetamide, 
Rochagan®, Roche, and currently produced By LAFEPE in Brazil). The problem with these 
drugs is that the significant side effects including weight loss, nausea and vomiting, rash, 
tissue abnormalities, leukopenia, neurotoxicity, psychosis, and peripheral neuropathy. On 
the other hand, Bnz can cause edema, fever, rash, peripheral neuropathy, lymphadenopathy, 
agranulocytosis, thrombocytopenic purpura, and joint and muscular pain. The use of these 
drugs during the acute phase of the disease is widely accepted, but its efficacy in the chronic 
phase is controversial [14].
The medicinal chemistry of Chagas disease has used different approaches in the search for 
new therapeutic entities. Some are oriented to the chemical development (synthesis) of new 
agents with interaction with key biomolecules for the parasite, or production of toxic spe-
cies [15, 16]. Also, the reposition and polypharmacology of drugs have been used [17]. Other 
strategies have been oriented to the identification and isolation of new agents of natural origin 
[18]. Despite these efforts, research work in this medical area in order to find new solutions 
to a problem that seems to have no end is therefore, of utmost importance [14]. This review 
seeks answers in nature and always remembers the primary motivation: that affected people 
lacking the necessary resources find in their natural habitat medicinal plants that provide a 
possible treatment endorsed by science, effective and without side effects.
2. Natural products research
The use of plants for curative purposes dates back to the beginning of human history. The 
man turned to nature in search of food and health. By means of successes and errors, he 
learned to know the plants that healed. This knowledge was transmitted from generation to 
generation and was increased with experimentation. Without the resources offered by nature, 
humans would not have survived. Gradually humans, by dominating nature, have broken 
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many of the ties that bind him. Today the medicine uses synthetic or semisynthetic drugs to 
relieve all diseases. Many of these drugs are beneficial, but many also, by misuse or abuse 
have lost their efficacy and in countless cases cause harmful side effects [19, 20].
In Latin American countries, the use of medicinal plants is the usual practice of indigenous 
groups and is frequently used by certain sectors of society [21]. This practice is usually an 
economic alternative to the prices imposed by the pharmaceutical industries and in many 
cases the only possibility of treatment [21, 22]. Most medicinal plants have multiple physi-
ological effects, due to the presence of more than one active principle. The latter correspond 
to chemical compounds of the plant, which are subject to variables, such as soil moisture, 
light conditions, temperature, date of planting and harvesting, drying conditions, and among 
others [23].
Fortunately, in recent years, there has been an increase in interest in the return to nature, and 
therefore, it is necessary to build a new relationship with our environment, leading a less 
artificial life and turning to plants not only to include them in our diet but also to alleviate 
our conditions [19].
Natural products contribute greatly to the history and landscape of new molecular entities 
(NMEs). An assessment of all FDA-approved NMEs reveals that natural products and their 
derivatives represent over one-third of all NMEs. By the end of 2013, the FDA had approved 
547 natural products and derivatives. Since the 1970s, the relative and then an absolute num-
ber of natural-product-based NMEs began to decline and today stand at fewer than one-quar-
ter (24%) or an average of 7.7 natural product NMEs per year [24]. Plant products represented 
more than one-fifth (22%) of all NMEs approved before 1950, declining by more than 50–8.7% 
since that time [24]. Over the past two decades, the pharmaceutical industry has shied away 
from research into natural products. Attention shifted toward combinatorial chemistry, 
which seemed to satisfy the need for compound libraries to keep up with high throughput 
assays based on newly discovered molecular targets. However, this approach did not result 
in improved productivity, nor did an increase in the number of new drugs. The number of 
NMEs reached a record low of 24 in 2004 with an average of 40–50 new approved drugs by 
year in the period of 1981–2014. In the same period of 1981–2014, 16 NMEs were approved as 
antiparasitic drugs. Newman and Cragg classified these NMEs as unaltered natural products, 
natural products derivatives, a synthetic drug, synthetic drug (natural product pharmaco-
phore), and mimic of the natural product (Figure 1). Among them, 68.7% are related to natu-
ral products [25, 26].
Izumi et al. reviewed the prospect of developing new drugs for the Chagas disease, on the 
screening of almost 400 species belonging to more than 100 plant families for activity against 
T. cruzi [27]. The plant extracts preparation methods have been very variable, from processes 
involving only one part of the plant to extract with different polarity solvents as well as using 
all part of the plant in the same solvent. Usually, the plant part in the study is the same that 
is used traditionally, but this does not assure that the accumulation of the active principles 
is maximum in the selected part. The plant extracts screened against different intracellular 
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forms of T. cruzi shows promising results. As a result, hexane extracts of Polygala sabulosa 
and aqueous extracts of Polygala cyparissias showed 50% inhibition of epimastigote growth 
after 72 h of treatment at concentrations of 1 and 2 μg/mL, respectively [28]. Ethanol extracts 
of Physalis angulata showed 50% inhibition of epimastigote growth after 120 h of treatment 
at a concentration of 2.9 μg/mL in Y strain and 7.4 μg/mL in Colombian strain [29]. Ethanol 
extracts of Baccharis trimera and Baccharis articulata showed 50% inhibition of epimastigote 
growth after 120 h of treatment at concentration 13.6 and 16.6 μg/mL in Tulahuen 2 strain, 
respectively [30]. For trypomastigotes, Piptadenia africana methanolic extract caused lysis in 
50% of the parasites at 4 μg/mL after 96 h [31], and a methanolic extract from Gardenia lutea 
also promoted the same effect at approximately 22 μg/mL after 72 h [32]. The essential oil 
from the fruits of Piper cubeba showed 50% inhibition of trypomastigote form at a concen-
tration of 45.5 μg/mL [33]. Surprisingly, by applying methanolic extracts of eight different 
species (Hypoestes forsskalii, Kleinia odora and Psiadia punctulata, Capparis spinosa, Euphorbia 
schimperiana and Ricinus communis, Marrubium vulgare, and Solanum villosum) an inhibition 
of 50% less than 0.25 μg/mL was found against the amastigote form with a treatment of 
7 days [34]. Also for amastigotes, methylene chloride extract from leaves of Conobea scopari-
oides showed 50% inhibition after 96 h at 1.3 μg/mL [35]. Ethanol extracts of Baccharis trimera 
and Baccharis articulata showed 50% inhibition of amastigote growth after 72 h of treatment at 
concentration 9.9 and 22.3 μg/mL in Dm28c strain, respectively [30]. Given that the financial 
resources for research on neglected diseases are usually low, most of the laboratories can-
not afford the maintenance of infected animal models or cell cultures to perform tests with 
the infective forms, trypomastigote, and amastigote. This leads to screenings of compounds 
performed only against non-infective forms, even when promising preliminary results are 
reached, the isolation of active compounds is not frequent. Despite the screening of hundreds 
Figure 1. Classification of antiparasitic NMEs approved by FDA in the period 1981–2014.
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of species, the major, possibly active compound was only isolated, identified, and evalu-
ated for antiparasitic activity in approximately 10% of the cases [27]. In vivo studies on the 
animal model of Chagas disease of plant extracts are less numerous than in vitro ones, but 
there are also reports of promising results. For example, Serjania yucatanensis ethanol leaves 
extract reduced 75% of the parasitemia in infected mice treatment at 100 mg/kg [36] and 
Aristeguietia glutinosa ethanol aerial parts extract reduced 50% of the parasitemia in infected 
mice at 50 mg/kg [37]. Plants extracts screening performed have been based on isolated 
efforts directed by research groups worldwide. Moreover, Pereira et al., after conducting an 
extensive bibliographic review for natural antichagasic products, conclude that there is an 
important geographic and ethnodirected component in the research initiatives on the rel-
evance of plant derivatives in the treatment of Chagas disease [38]. The main obstacle that 
stops research work is the gap that needs to be bridged toward clinical phases, given the dif-
ficulties in scaling the purification of the active compound, standardization of the chemical 
profile of whole extracts, and among others. The principal common factor that delays clinical 
phase is the lack of investment for the development of these products at this stage of investi-
gation [39]. Figure 2 summarize the progress and current status of research and development 
of natural products for the Chagas disease.
Figure 2. Current status of research and development of natural products for the Chagas disease.
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In many cases, the isolation of compounds leads to the loss of biological activity or to the 
achievement of a really low extraction yield. That is why work with whole extracts should be 
re-considered as a possible source of new treatment drugs for the Chagas disease. Given the 
low economic potential of the majority of the affected population, it is clear that the develop-
ment of new treatment drugs should consider cost-effectiveness. In the search for new thera-
pies for Chagas from plant origin, low cost and easy access for patients, we propose the use 
of new methodologies to overcome the existing challenges. The use of plant metabolomics 
technique is proposed as an option with high potential for the identification of biomarkers 
that could allow the standardization of chemical profiles of whole plant extracts that can be 
formulated in a simple, quick, and low-cost dosage.
3. Plant metabolomics
Metabolomics can be defined as the detection and quantification of all metabolites of low 
molecular weight in an organism at a given time and in certain conditions. However, adjust-
ing to our purposes and applications can be better defined as the area of research that seeks to 
obtain the metabolic fingerprints to detect the differences between them and propose hypoth-
eses that explain the differences.
The field of metabolomics in science marks its beginning when Devaux and Horning publish 
their research work in the metabolic profile where they apply gas chromatography coupled 
with mass spectrometry (GC/MS) for the analysis of extracts of human tissues and urine [40]. 
Immediately, the interest of different groups in using the metabolic profiles for the diagnosis 
and follow-up of different pathologies [41]. During the 1970s metabolomics studies expanded 
to a wide range of activities including: novel techniques for detection and elucidation of insect 
hormones [42], identification of natural products of marine origin [43], and chemotherapeutic 
agents derived from plant extracts (e.g.: Hyptis tomentosa) [44]. At the beginning of the 1980s, 
the first work on automated metabolic analysis emerged [45] and by the middle of the decade, 
the first works on metabolic profiling were published using nuclear magnetic resonance 
(NMR) and high-performance liquid chromatography (HPLC) [46–48]. In order to analyze 
the mechanism of action of herbicides besides performing GC/MS, a new global approach was 
developed in 1991 [49]. As a result of scientific cooperation, by the end of twentieth century, it 
was possible to apply novel technologies to metabolomics and methods of extraction, encour-
aging the development of metabolite databases [50], which allowed the global development 
of complete metabolomes [51].
In the last decade, metabolomics has developed as an important field within plant science 
and natural product chemistry [52–56]. Metabolic fingerprint, also known as a metabolic 
profile, is an objective analytical approach that seeks to quantify a group or groups of com-
pounds found in an organism or group of organisms. The metabolic profile with gas chroma-
tography and high-performance chromatography coupled to mass spectrometry or proton 
magnetic resonance (1H NMR) has been successfully used the study plant biochemistry, 
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chemotaxonomy, ecology, pharmacology, and quality control of medicinal plants [57, 58]. 
The application of NMR has already been demonstrated as a suitable and sufficient method 
to carry out this type of analysis, since it allows simultaneous detection of various groups 
of secondary metabolites, in addition to abundant primary metabolites [59]. In addition, 1H 
NMR spectroscopy has a great advantage over the other techniques, the signal intensity is 
dependent only on the molar concentration of the metabolites, allowing the direct compari-
son of these present in the sample [60, 61]. In the last years, several reports on the evaluation 
of the metabolic differences in Cannabis sativa, Vanilla planifolia, Vitis spp. and Catharanthus 
roseus, among others, and in the classification of Ilex species based on their metabolome 
are published [57, 60, 62, 63]. The major disadvantage in using NMR spectroscopy in the 
metabolomic analysis is overlapping signals, which however, can be solved by using differ-
ent 2D-NMR techniques [52, 60, 63].
A typical approach of NMR-based metabolomic application for the identification of new natu-
ral products with biological activity that are part of whole extracts (Figure 3) was applied for the 
identification of new natural products with anti-T. cruzi activity in Uruguayan plants. Eighty 
samples of ethanolic extracts from different botanic parts, soils, and seasons, of Uruguayan 
specimens: Baccharis trimera, Baccharis articulata, Baccharis usterii, Hydrocotyle bonariensis, 
Figure 3. Typical approach of NMR-based metabolomic to identify new active compounds on plant extracts.
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Achyrocline satureioides, Taraxacum officinalis, and Plantago major were used. As a primary screen-
ing the anti-T. cruzi activity against the epimastigotes showed that three species of Baccharis 
genus and Hydrocotyle bonariessis displayed well to excellent antiproliferative activity. The most 
active fractions were additionally evaluated for their activity on amastigotes and also for cyto-
toxicity against mammalian cells. For the identification of the active principles was applied 
using nuclear magnetic resonance-based metabolomic. Through the metabolomic study of the 
relationship between the changes in chemical profiles and the biological activities, it was pos-
sible to identify the main active principles of the extracts and also the compounds responsible 
for cytotoxic activity [30]. The technique also allowed us to infer the parts of the plants with 
greater accumulation of the active compounds as well as the conditions for their maximum 
expression (soil type, harvest season).
The development of drugs from wild plants with simple growing requirements, allow us to 
consider the future possibility of creating standardized cultivars, in order to perform in vivo 
assays and clinical trials. We performed the standardization of cultivars of Baccharis trimera, 
Baccharis articulata, and Baccharis usterii with relevant results in the expression of their active 
molecules against T. cruzi. The propagation was made by cloning mother plants collected 
from wild nature and developing their cuttings on an environment controlled greenhouse 
(Figure 4). The plant extracts prepared from the standardized cultivars are being studied in 
vivo in a murine model of the Chagas disease.
When plant cultivars are performed for possible pharmaceutical uses it is important to con-
sider World Health Organization (WHO) guidelines on good agricultural and collection prac-
tices (GACP) for medicinal plants [64].
Figure 4. Cultivar propagation of Baccharis spp. for standardization of their chemical profile for extracts preparation to 
be used on in vivo test for the Chagas disease.
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4. Good agricultural and collection practices (GACP)
Medicinal plant resources are being harvested in increasing volumes, largely from wild popu-
lations. Indeed, demand for wild resources has increased by 8–15% per year in Europe, North 
America, and Asia in recent decades. Various sets of recommendations relating to the con-
servation of medicinal plants have been developed, such as providing both in situ and ex situ 
conservation [65].
The harvest of plants that had a wild growth is considered an efficacious source for medici-
nal purposes, but domestic cultivation is also a widely used and accepted practice [66–68]. 
Indeed, domestic cultivation provides advantages for the production of medicinal plants, 
allowing control for toxic components, avoiding pesticides, increasing the content of active 
compounds, and having precise information for the identification of botanical origin [69]. In 
this way, controlling the growing conditions is a relevant tool for production stability and 
to improve the yields of secondary metabolites, which are frequently the active compounds. 
Cultivation standards include providing optimal levels of water, nutrients and other envi-
ronmental factors such as light, humidity, temperature, in order to improved yields of target 
products [70]. Moreover, controlled cultivation contributes to decrease the harvest of medici-
nal wild plant resources, also having a positive impact on their prices [71, 72].
This knowledge has been translated into good agricultural and collection practices for medici-
nal plants that were developed in order to regulate production, assess quality, and lead to the 
standardization of herbal drugs [73]. The application of these formal practices, summarized 
in GACP approaches, is important to ensure high quality, safe and pollution free herbal drugs 
(or crude drugs) [74]. A wide range of problems are controlled by applying GACP including 
the ecological environment of production, germplasm, cultivation, and collection methods, as 
well as quality aspects for pesticide detection, authentication in macro and microscopic terms, 
chemical identification of active compounds, and detection of metal elements [75]. Given the 
importance of GACP, many countries actively promote their implementation; however, there 
is still an important gap to bridge concerning knowledge and implementation. This dispar-
ity is given by the difficulties encountered for training farmers and other relevant actors for 
medicinal plant production, such as handlers and processors. While these kind practices are 
strictly applied at the level of pharmaceutical producers that are used to work in order to meet 
quality control requirements, it has been more difficult to successfully introduce this practices 
standard at the level of agricultural producers, handlers, and processors of medicinal plant 
material. It will be important to focus the efforts on training farmers and other relevant actors 
to ensure that GACP is adopted and favor the obtainment of high-quality medicinal plant 
materials [64].
Currently, organic farming is increasingly receiving public attention, given that these practices 
include a vision of sustainability and economically relevant business without forgetting the 
well-being of workers and creates integrated production systems for medicinal plants [76, 77]. 
The main characteristic of organic farming is the avoidance of synthetic fertilizers, pesticides 
or herbicides, and reaching the standards of organic certification. The defining characteristic 
of organic farming is the non-use of synthetic fertilizers, pesticides, and herbicides, which are 
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not allowed according to many current organic certification standards in Europe and North 
America. Instead of applying synthetic fertilizers, organic fertilizers may be continuously 
supplied to the soil, contributing nutrients, and improving soil stability, while positively 
impacting the biosynthesis of essential substances. Furthermore, organic farming generates 
high-quality products and better yields, while taking care of the conservation of those plants. 
Indeed, when organic fertilizers were applied to the cultivation of Chrysanthemum balsamita, 
the biomass yield was increased and its essential oil content was higher that those free from 
organic fertilizers [78]. Above all, organic farming is a benign practice for our environment, 
based upon renewable and sustainable resources that favor the maintenance of a biological 
equilibrium in the medicinal plants and their ecological systems [74, 76]. For these reasons, 
the application of organic farming practices is highly relevant for medicinal plant production, 
encouraging a sustainable, and long-term systemic approach [77].
5. The novel strategy proposed to obtain effective, cheap and 
standardized phytoterapeutic for treat Chagas disease
Based on the use of metabolomic and the GACP, the following workflow is proposed for 
obtaining phytoterapeutics for Chagas disease treatment (Figure 5).
Figure 5. Workflow proposed for research and development of new natural products for Chagas disease treatment.
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6. Conclusions
Traditional medicines, particularly herbal medicines have been increasingly used worldwide 
during the last two decades. On Chagas disease research many plant extracts were evaluated 
worldwide with relevant results but in most cases, the development is slowed in the scaling 
of the isolation of the active principle or by the lack of standardization of chemical profiles of 
the whole extracts. We presented a new novel strategy for the production of effective, cheap 
and standardized phytotherapeutic products through the use of plant metabolomics tech-
nique and the standardization of medicinal plants cultivars applying good agricultural and 
collection practices.
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